Skip to content

Intervention trial of the effect of consumption of commercially available milk on human hormone levels

An experimental study of changes in human hormone exposure caused by consumption of commercial milk

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040525
Enrollment
Unknown
Registered
2020-12-01
Start date
2011-07-20
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

A: High Dose Milk Drinking Group:500ml (55g milk powder) of liquid milk daily
A: Low-dose milk group:300ml (33g milk powder) of liquid milk daily
B: Low dose control group:Daily syrup (45g sugar)
B: High-dose control group:Daily syrup (108g sugar)
B: Low dose milk drinking group:250ml of liquid milk daily
B: High dose milk drinking group:600ml of liquid milk daily

Sponsors

Nanjing Medical University School of Public Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 30 Years

Inclusion criteria

Inclusion criteria: Female: 1. 22-26 years old; 2. Normal weight with a BMI between 18.5 and 23.9; 3. Regular menstrual cycle, with a stable menstrual cycle of 28-32 days for six months; 4. Have not recently taken oral contraceptives, or other hormonal drugs; 5. No significant experience with lactose intolerance. Children: 1. The age range is 7 to 9 years old; 2. Half male and half female, half normal weight and half obese children; 3. No history of milk allergy; 4. No or mild lactose intolerance; 5. Be able to drink the prescribed amount of milk (up to 1000ml+) in 10 minutes; 6. With the consent of parents and children, they are willing to participate in the experiment.

Exclusion criteria

Exclusion criteria: Female: 1. Females with diseases that may interfere with the results of the experiment, such as estrogen-related diseases such as ovarian cysts, uterine fibroids, cervical cancer, breast cancer, lobular hyperplasia, endometrial cancer, endometriosis, polycystic ovary syndrome, etc., after a physical examination; 2. Not be able to cooperate with various experimental arrangements. Children: 1. Children diagnosed with clinical precocious puberty; 2. Children with major diseases such as leukemia, diabetes, heart disease, etc.; 3. Failure to comply with the experimental protocol.

Design outcomes

Primary

MeasureTime frame
Free Estradiol;Free Progesterone;Testosterone;Luteinizing Hormone;Follicle stimulating hormone;Prolactin;Conjugated Estradiol;Conjugated Progesterone;

Countries

China

Contacts

Public ContactZhixu Wang

Nanjing Medical University School of Public Health

zhixu.wang@126.com+86 13675173338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026